CAMBRIDGE, United Kingdom, LANGENHAGEN, Germany & SAN ANTONIO, Texas--(BUSINESS WIRE)--Lab21 Ltd and AdnaGen AG announced today that they have entered into an exclusive service and distribution agreement for AdnaGen’s proprietary CE-certified circulating tumor cell diagnostic assays in the United Kingdom and Ireland. These tests are based on the capture of circulating tumor cells (CTCs) from blood and subsequent detection of tumor-associated biomarkers.
